|
Approval Withheld for Expanded Label on J&J Arthritis Drug Simponi
Janssen Biotech has put on hold plans to extend sales of rheumatoid and psoriatic arthritis drug Simponi to prevent the progression of psoriatic arthritis, pending resolution of FDA concerns about the expanded label.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives